On the recordSeptember 21, 2016
Our bill is the product of consultations with a wide range of stakeholders, as Senator Feinstein has mentioned, and it would give the FDA broader oversight.
Source
congress.govOur bill is the product of consultations with a wide range of stakeholders, as Senator Feinstein has mentioned, and it would give the FDA broader oversight.
Collins emphasizes stakeholder involvement in creating the bill for FDA oversight.
Share & report
More from Susan Collins
That procedural motion does not predict my vote on final passage. I will be filing a number of amendments.
My vote against this bill stems primarily from the harmful impact it will have on Medicaid, affecting low-income families and rural health care providers like our hospitals and nursing homes.